Protective actions of melatonin against heart damage during chronic Chagas disease

Luiz Gustavo Rodrigues Oliveira1, Christian Collins Kuehn, Carla Domingues dos Santos

  • 1Laboratório de Parasitologia, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto FCFRP-USP, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.

Acta Tropica
|September 24, 2013
PubMed

Insights

Melatonin therapy effectively combats cardiac inflammation in chronic Chagas disease. This study shows melatonin reduces harmful immune responses and protects the heart in infected rats.

Area of Science:

  • Immunology
  • Pharmacology
  • Cardiology

Background:

  • Chronic Chagas disease is characterized by myocarditis, fibrosis, and organ dysfunction.
  • Alternative treatments are crucial for modulating host immune responses in Chagas disease.

Purpose of the Study:

  • To evaluate the anti-inflammatory effects of melatonin during the chronic phase of Chagas disease.
  • To assess melatonin's efficacy in protecting against cardiac damage caused by Trypanosoma cruzi infection.

Main Methods:

  • Male Wistar rats were infected with Trypanosoma cruzi and treated with melatonin (50mg/kg/day) during the chronic phase.
  • Evaluated immune markers (TNF-α, IL-10, nitrite), cardiac inflammation, heart weight, and serum CK-MB levels.

Main Results:

  • Melatonin treatment significantly increased IL-10 and decreased nitrite and TNF-α concentrations.
  • Reduced heart weight, serum CK-MB levels, and cardiac inflammatory foci were observed in melatonin-treated rats.
  • Melatonin demonstrated significant cardioprotective effects against T. cruzi-induced inflammation.

Conclusions:

  • Melatonin therapy is effective in mitigating the cardiac inflammatory response in chronic Chagas disease.
  • Melatonin shows promise as a therapeutic agent for managing Chagas disease cardiomyopathy.

Related Concept Videos

Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...